WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H412656
CAS#: 165800-08-8 (trisodium hydrate)
Description: Zoledronate trisodium is a Bone Resorption Inhibitor and Osteoporosis Therapy Adjunct
Hodoodo Cat#: H412656
Name: Zoledronate trisodium hydrate
CAS#: 165800-08-8 (trisodium hydrate)
Chemical Formula: C25H39N10Na15O37P10
Exact Mass: 0.00
Molecular Weight: 1,726.200
Elemental Analysis: C, 17.40; H, 2.28; N, 8.11; Na, 19.98; O, 34.29; P, 17.94
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 118072-93-8 (free acid) 165800-06-6 (free acid hydrate) 131654-46-1 (disodium) 827573-11-5 (trisodium) 165800-07-7 (disodium hydrate) 165800-08-8 (trisodium hydrate)
Synonym: Zoledronate trisodium, Zoledronate trisodium hydrate
IUPAC/Chemical Name: Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-, trisodium compound with water (5:2)
InChi Key: HYMYRPXSMHJPGD-UHFFFAOYSA-A
InChi Code: InChI=1S/5C5H10N2O7P2.15Na.2H2O/c5*8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;;;;;;;;;;;;;;;;;/h5*1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);;;;;;;;;;;;;;;;2*1H2/q;;;;;15*+1;;/p-15
SMILES Code: OC(P([O-])([O-])=O)(P([O-])(O)=O)CN1C=CN=C1.OC(P([O-])([O-])=O)(P([O-])(O)=O)CN2C=CN=C2.OC(P([O-])([O-])=O)(P([O-])(O)=O)CN3C=CN=C3.OC(P([O-])([O-])=O)(P([O-])(O)=O)CN4C=CN=C4.OC(P([O-])([O-])=O)(P([O-])(O)=O)CN5C=CN=C5.[H]O[H].[H]O[H].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 1,726.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082. Epub 2018 Oct 1. PMID: 30575489.
2: Bergua A, Hohberger B. Zoledronsäure-induzierte Panuveitis [Zoledronate- induced panuveitis]. Ophthalmologe. 2018 Jul;115(7):592-594. German. doi: 10.1007/s00347-017-0538-3. PMID: 28748264.
3: Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. J Bone Miner Res. 2019 Dec;34(12):2220-2228. doi: 10.1002/jbmr.3853. Epub 2019 Oct 14. PMID: 31433518.
4: Leong I. Zoledronate prevents fractures in osteopenia. Nat Rev Endocrinol. 2018 Dec;14(12):688. doi: 10.1038/s41574-018-0116-z. PMID: 30353074.
5: Dong W, Qi M, Wang Y, Feng X, Liu H. Zoledronate and high glucose levels influence osteoclast differentiation and bone absorption via the AMPK pathway. Biochem Biophys Res Commun. 2018 Nov 10;505(4):1195-1202. doi: 10.1016/j.bbrc.2018.10.059. Epub 2018 Oct 13. PMID: 30322621.
6: Zhao Z, Shen W, Zhu H, Lin L, Jiang G, Zhu Y, Song H, Wu L. Zoledronate inhibits fibroblasts' proliferation and activation via targeting TGF-β signaling pathway. Drug Des Devel Ther. 2018 Sep 17;12:3021-3031. doi: 10.2147/DDDT.S168897. PMID: 30271117; PMCID: PMC6147205.
7: He Y, Bao W, Wu XD, Huang W, Chen H, Li Z. Effects of Systemic or Local Administration of Zoledronate on Implant Osseointegration: A Preclinical Meta- Analysis. Biomed Res Int. 2019 Sep 22;2019:9541485. doi: 10.1155/2019/9541485. PMID: 31663000; PMCID: PMC6778941.
8: Zhao QH, Zhang XS, Wu K, Zhang J, Xia TF, Chen J, Qin ZS, Pang LQ. Preparation of Zoledronate liposome and its impact on apoptosis of Kupffer cells in rat liver. Acta Cir Bras. 2018 Dec;33(12):1052-1060. doi: 10.1590/s0102-865020180120000002. PMID: 30624510.
9: Schenk A, Lux C, Lane J, Martin O. Evaluation of Zoledronate as Treatment for Hypercalcemia in Four Dogs. J Am Anim Hosp Assoc. 2018 Nov/Dec;54(6):e54604. doi: 10.5326/JAAHA-MS-6681. Epub 2018 Oct 1. PMID: 30272485.
10: Zandi M, Shokri A, Mousavi M, Rajaei S, Mohammad Gholi Mezerji N. Does zoledronate therapy make mandibular bone susceptible to fracture? A radiographical and biomechanical study in rats. Injury. 2018 Oct;49(10):1746-1749. doi: 10.1016/j.injury.2018.07.006. Epub 2018 Jul 6. PMID: 30007517.